Cite
HARVARD Citation
Roussel, M. et al. (2020). Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. Lancet. 7 (12), pp. e874-e883. [Online].